Product Code Database
BK-NM-AMT, or βk-NM-αMT, also known as β-keto- N-methyl-αMT or α, N-dimethyl-β-ketotryptamine, as well as 3-indoylmethcathinone, is a serotonin–dopamine releasing agent (SDRA) and putative entactogen of the tryptamine, α-alkyltryptamine, and β-ketotryptamine families. Along with certain other tryptamines, such as α-ethyltryptamine (αET), 5-chloro-αMT and 5-fluoro-αET, it is one of the few SDRAs known.
The drug is the N-methyl group and β-ketone analogue of α-methyltryptamine (αMT). It is a cathinone-like tryptamine and can be thought of as the tryptamine or indole analogue of the phenethylamine methcathinone. The values of BK-NM-AMT for monoamine release are 41.3nM for serotonin and 92.8nM for dopamine in rat brain , whereas it only induced 55% release of norepinephrine at a concentration of 10μM.
Several 5-halogenation derivatives of BK-NM-AMT have also been described. These include BK-5F-NM-AMT, BK-5Cl-NM-AMT, and BK-5Br-NM-AMT. Like BK-NM-AMT, they induce serotonin and dopamine release. In contrast to many other tryptamines however, these novel β-keto-substituted tryptamine derivatives are inactive as of serotonin receptors including the 5-HT1, 5-HT2, and 5-HT3 receptors. In addition, unlike other α-alkyltryptamines like αMT, these compounds are inactive as monoamine oxidase inhibitors (MAOIs).
BK-NM-AMT and its 5-halogenated analogues were by Matthew Baggott and Tactogen in late 2024.
| + Monoamine release of BK-NM-AMT and related compounds (, nM) | ||||||
| Notes: The smaller the value, the more strongly the substance releases the neurotransmitter. The bioassay were done in rat brain and human potencies may be different. See also Monoamine releasing agent § Activity profiles for a larger table with more compounds. | ||||||
|
|
